SCHEMBL17535758

SCHEMBL17535758

CC(C)[Si](OCc1ccc(OCc2ccccc2)c(C2CC2)n1)(C(C)C)C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.39
STAT3 P40763 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTR1A P08908 2/20 0.38
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
MAPK1 P28482 2/20 0.36
MAPT P10636 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM1A O60341 2/20 0.36
FDFT1 P37268 1/20 0.35
CCR5 P51681 1/20 0.34
ALOX5AP P20292 2/20 0.34
FEN1 P39748 1/20 0.34
MCHR1 Q99705 1/20 0.34
ALDH1A1 P00352 2/20 0.34
LIPE Q05469 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17535527 0.82 PDE10A (0.31)
SCHEMBL17535463 0.81 MAPK1 (0.41) HTTSTAT3SMN1; SMN2MAPK1MAPT
SCHEMBL17535634 0.79 AOC3 (0.41) HTTSTAT3SMN1; SMN2HTR1AMAPK1
SCHEMBL17535586 0.75 PDE10A (0.34)
SCHEMBL3565081 0.73 MAPK1 (0.39) HTTSTAT3SMN1; SMN2HTR1AMAPK1
SCHEMBL13343554 0.73 L3MBTL1 (0.46) HTTSTAT3SMN1; SMN2SLC6A4MAPK1
SCHEMBL24976600 0.72 SLC6A4 (0.43) HTTSTAT3SMN1; SMN2HTR1ASLC6A2
SCHEMBL1315107 0.72 TSHR (0.46) HTTSLC6A2SLC6A4SLC6A3MAPK1
SCHEMBL31434505 0.65 APP (0.58) HTTSMN1; SMN2MAPK1MAPTTDP1
SCHEMBL16333867 0.65 LTA4H (0.54) HTR1ASLC6A2SLC6A4SLC6A3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970331-B1 SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS TAKEDA PHARMACEUTICALS CO (JP) 2017-05-17 EP disclosed
US-9605000-B2 Spiro azetidine isoxazole derivatives and their use as SSTR antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-28 US disclosed
US-20160060273-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060273-A1 HETEROCYCLIC COMPOUND SSTR5, SSTR1, SSTR2 HTT 1278/4885STAT3 236/4885SMN1; SMN2 1672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.